Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects

Dalfampridine is a drug used to improve walking in multiple sclerosis (MS) patients. Approved in 2010, it is contraindicated in patients who have a history of seizures and/or renal disease. In this case report, we present a patient who did not have either of these contraindications yet had a seizure...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaman, Rameez, Goldberg, Elliott, Zomorodi, Naseem, Acharya, Vinita J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808083/
https://www.ncbi.nlm.nih.gov/pubmed/35145789
http://dx.doi.org/10.7759/cureus.20884
_version_ 1784643810193571840
author Zaman, Rameez
Goldberg, Elliott
Zomorodi, Naseem
Acharya, Vinita J
author_facet Zaman, Rameez
Goldberg, Elliott
Zomorodi, Naseem
Acharya, Vinita J
author_sort Zaman, Rameez
collection PubMed
description Dalfampridine is a drug used to improve walking in multiple sclerosis (MS) patients. Approved in 2010, it is contraindicated in patients who have a history of seizures and/or renal disease. In this case report, we present a patient who did not have either of these contraindications yet had a seizure episode with the only contributing factor being the use of dalfampridine.
format Online
Article
Text
id pubmed-8808083
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88080832022-02-09 Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects Zaman, Rameez Goldberg, Elliott Zomorodi, Naseem Acharya, Vinita J Cureus Emergency Medicine Dalfampridine is a drug used to improve walking in multiple sclerosis (MS) patients. Approved in 2010, it is contraindicated in patients who have a history of seizures and/or renal disease. In this case report, we present a patient who did not have either of these contraindications yet had a seizure episode with the only contributing factor being the use of dalfampridine. Cureus 2022-01-03 /pmc/articles/PMC8808083/ /pubmed/35145789 http://dx.doi.org/10.7759/cureus.20884 Text en Copyright © 2022, Zaman et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Emergency Medicine
Zaman, Rameez
Goldberg, Elliott
Zomorodi, Naseem
Acharya, Vinita J
Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title_full Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title_fullStr Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title_full_unstemmed Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title_short Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
title_sort increasing patient safety among multiple sclerosis (ms) drug dalfampridine users by expanding awareness of the serious side effects
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808083/
https://www.ncbi.nlm.nih.gov/pubmed/35145789
http://dx.doi.org/10.7759/cureus.20884
work_keys_str_mv AT zamanrameez increasingpatientsafetyamongmultiplesclerosismsdrugdalfampridineusersbyexpandingawarenessoftheserioussideeffects
AT goldbergelliott increasingpatientsafetyamongmultiplesclerosismsdrugdalfampridineusersbyexpandingawarenessoftheserioussideeffects
AT zomorodinaseem increasingpatientsafetyamongmultiplesclerosismsdrugdalfampridineusersbyexpandingawarenessoftheserioussideeffects
AT acharyavinitaj increasingpatientsafetyamongmultiplesclerosismsdrugdalfampridineusersbyexpandingawarenessoftheserioussideeffects

Ejemplares similares